Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Non-Current Deferred Tax Liability (2016 - 2026)

Argenx Se's (ARGX) quarterly Non-Current Deferred Tax Liability came in at $69.0 million in Q2 2026, down 99.93% on a YoY basis from $100.5 billion in Q2 2025, and down 19.77% quarter-over-quarter from $86.0 million in Q4 2025.

Analysis

Argenx Se (ARGX) Non-Current Deferred Tax Liability (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Non-Current Deferred Tax Liability for 10 consecutive years, with $69.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Deferred Tax Liability fell 99.93% year-over-year to $69.0 million; the trailing twelve-month figure through Jun 2026 stood at $69.0 million (down 99.93% YoY), and the FY2025 full-year result was $86.0 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability retreated to $69.0 million in Q2 2026 per ARGX's latest filing, from $86.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $100.5 billion in Q2 2025 and bottomed at $5.0 million in Q2 2024.
  • Historically, Non-Current Deferred Tax Liability has averaged $14.3 billion across 5 years, with a median of $77.5 million in 2025.
  • The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability soared 2011654.1% in 2025, then tumbled 99.93% in 2026.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $8.4 billion in 2022, then plunged by 38.67% to $5.2 billion in 2023, then slumped by 99.9% to $5.0 million in 2024, then jumped by 1622.07% to $86.0 million in 2025, then declined by 19.77% to $69.0 million in 2026.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $69.0 million, $86.0 million, and $100.5 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 69.00 Mn
Dec 31, 2025 86.00 Mn
Jun 30, 2025 100.47 Bn
Jun 30, 2024 4.99 Mn
Dec 31, 2023 5.16 Bn
Jun 30, 2023 8.89 Mn
Dec 31, 2022 8.41 Bn
Jun 30, 2022 7.66 Mn
Dec 31, 2021 6.44 Bn
Jun 30, 2021 12.39 Mn
Dec 31, 2020 1.45 Bn
Jun 30, 2020 959,371.77
Jun 30, 2018 359,226.77
Dec 31, 2017 186,034.34
Jun 30, 2017 179,226.54
Dec 31, 2016 175,995.05